Insilico Medicine to Address AI Drug Discovery Challenges at BIO Convention
Insilico Medicine, a clinical stage artificial intelligence (AI)-powered drug discovery company , is set to tackle key issues in AI drug discovery at the upcoming BIO International Convention in San Diego from June 3-6. The company’s leadership, including Chief Business Officer Michelle Chen, PhD; Vice President for Business Development Keith Mikule, PhD; Head of Business Development, APAC Jue Wang, PhD; and President of Insilico Medicine Taiwan Jimmy Yen-Chu Lin, PhD, will be present to discuss Insilico’s latest pipeline developments. Advancing AI Drug Discovery At the convention, Insilico will showcase its groundbreaking pipeline, which features over 30 AI-designed small molecule inhibitors targeting diseases such as cancer, inflammatory bowel disease, and fibrosis. With seven candidates already in clinical stages, Insilico’s innovative approach holds promise for therapeutic advancements. The company’s representatives will be available at Booth #5657 to engage in discussions about th...